Johnson & Johnson posted an earnings and revenue beat for Q314, but we believe that the company will see headwinds in the coming quarters. We see sales of Olysio tailing off sharply following the approval of Harvoni, and dollar strength paring back earnings growth outside of the US. With the global economic outlook souring, we expect J&J to feel the impact given its international exposu...
Complete the trial form to receive a free issue of Pharma and Healthcare Insight sent to your email address. The Pharma and Healthcare Insight provides you with in-depth country by country data, analysis and forecasts.
START A FREE TRIAL TODAY
STEP 2: SELECT PRODUCTS
Please select the free products you would like to trial:
Thank you for your interest in Pharma and Healthcare Insight
You will shortly receive an e-mail with link(s) to a full version of the newsletter(s) you selected. A member of our Client Services team will be in touch soon to receive your feedback on the newsletters and arrange a convenient time for a free demonstration of the full service. If your enquiry is urgent, please email our team here
Business Monitor International -
A Fitch Group Company